PT - JOURNAL ARTICLE AU - Katie Love AU - Ricardo MF da Costa AU - Manfred Beckmann AU - Anna Morley AU - Rahul Bhatnagar AU - Nick Maskell AU - Luis AJ Mur AU - Keir E Lewis TI - Metabolomics differentiate cancer from non-cancer pleural effusions based on steroid lipids and acyl carnitines AID - 10.1101/2020.07.27.20162958 DP - 2020 Jan 01 TA - medRxiv PG - 2020.07.27.20162958 4099 - http://medrxiv.org/content/early/2020/07/29/2020.07.27.20162958.short 4100 - http://medrxiv.org/content/early/2020/07/29/2020.07.27.20162958.full AB - Objective To identify and detect metabolomic markers to differentiate cancer related from other pleural effusions.Material and methods Un-targeted flow infusion electrospray mass spectrometry was used on a cohort of 100 samples from benign and malignant pleural effusions (12 primary lung cancers, 14 mesotheliomas, 24 other cancers, 25 congestive cardiac failure, 22 parapneumonic effusion, 3 empyema). Standard metabolomic statistical models for analysis were performed.Results Five novel markers were identified using univariate and multivariate receiving operator curve analyses using five discriminant features yielding a diagnostic accuracy of above 0.91 (95% CI: 0.839-0.976) with a sensitivity of 0.97 (95% CI 0.952-0.979) and specificity 0.87 (95% CI 0.852-0.894).Conclusion Individual biomarkers with the highest accuracy (>0.84) were all raised in cancer and are involved in metabolism of sterol-lipids and acyl carnitines linked to β-oxidation. Our markers performed better than those previously published. Further, these published markers failed to achieve their stated accuracies in our data.Competing Interest StatementThe authors have declared no competing interest.Clinical Trialthis was a prospective study based on biobanked samples.Funding StatementRdC was funded by a Tenovus iGrant TIG2016-26. KL is supported by a Knowledge Economy Skills Scholarship (KESS 2) and further supported by European Social Funds (ESF).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:National Health Service (UK); Health Research Authority https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/novel-technologies-for-diagnosing-and-monitoring-pulmonary-diseases/All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesdata are uploaded as metadata and are freely availableCCFCongestive Cardiac FailureCOPDChronic Obstructive Pulmonary DiseaseCPPEComplicated Parapneumonic EffusionFIE-MSFlow Infusion Electrospray ion Mass SpectrometryIPFIdiopathic Pulmonary FibrosisPCAPrincipal Component AnalysesROCReceiver Operating CharacteristicAUCArea under the CurveVIPVariable Importance in ProjectionRFRandom Forest